Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about APMD, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2027-02-28 | AD109 (Oxnimbi) | NDA | 66% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| AD109 | OSA | Phase 3 · NCT05811247 | Completed |
| AD128 | Sleep Apnea, Obstructive | Phase 2/3 · NCT04394143 | Completed |
| Aroxybutynin | OSA | Phase 3 · NCT06566820 | Enrolling by invitation |
| AD981 | Obesity Hypoventilation Syndrome (OHS) | Phase 2 · NCT05448443 | Completed |
| SAS0421c | Sleep Apnea | Phase 1/2 · NCT03892772 | Completed |
| SAS0421b | Sleep Apnea | Phase 1/2 · NCT03892772 | Completed |
| SAS0421a | Sleep Apnea | Phase 1/2 · NCT03892772 | Completed |
| R-oxybutynin | Obstructive Sleep Apnea | Phase 2 · NCT04580394 | Completed |
| Period C | OSA | Phase 2 · NCT05793684 | Completed |
| Period B | OSA | Phase 2 · NCT05793684 | Completed |
| Period A | OSA | Phase 2 · NCT05793684 | Completed |
| Dosing 1: Atomoxetine | Obstructive Sleep Apnea | Phase 1/2 · NCT05101122 | Completed |
| AD036 | Obstructive Sleep Apnea | Phase 2 · NCT04445688 | Completed |
| AD504 | OSA - Obstructive Sleep Apnea | Phase 2 · NCT05071612 | Completed |
| AD313 | Obstructive Sleep Apnea | Phase 1/2 · NCT05101122 | Completed |
| AD182 | Obstructive Sleep Apnea | Phase 2 · NCT04645524 | Completed |
Also used in these trials (approved or third-party drugs, not APMD's own candidates): Mannitol, Atomoxetine Hydrochloride, Atomoxetine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
APMD holds $172.8M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 8 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when APMD files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Ameriprise Financial, Inc. | Institution (13G, 5%+) | 7,476,992 | 17.96% | 2026-07-31 |
| Morningside Venture Investments Ltd 10% owner |
Insider | 7,228,337 | 17.36% | 2026-08-03 |
| Alpha Wave Ventures GP, Ltd 10% owner |
Insider | 7,054,956 | 16.95% | 2026-08-03 |
| SHIONOGI & CO LTD | 5%+ holder (13G) | 2,953,817 | 7.10% | 2026-09-30 |
| Tao Capital Management LP | 5%+ holder (13G) | 2,178,138 | 5.23% | 2026-07-31 |
| Lawrence G. Miller Director · +2.25M options |
Insider | 459,092 | 1.10% | 2026-08-03 |
| Dennis Patrick Molnar President · +691,732 options |
Insider | 58,014 | 0.14% | 2026-07-30 |
| Paul J Sekhri Director · +191,706 options |
Insider | 12,500 | 0.03% | 2026-07-30 |
Share count 41,630,779 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for APMD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →